Vor Bio Appoints David Zaccardelli to Board of Directors

About this update from Vor Biopharma Inc.

BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. With more than 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully built and led companies through late-stage development, regulatory approval, and commercial launch. "We are excited to welcome David to the Board of Directors at an important stage in the company's evolution," said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. "David is a proven biotech operator with a distinguished track record of leading companies through periods of significant growth, from late-stage development to commercial execution. His experience building organizations, launching medicines, and creating shareholder value will be invaluable as we advance telitacicept through global Phase 3 development and build a leading immunology company." Dr. Zaccardelli served as President, Chief Executive Officer, and on the board of directors of Verona Pharma from February 2020 until its acquisition by Merck for $10 billion in October 2025. During his tenure, Verona advanced from a clinical-stage company to a commercial-stage organization, successfully completing two Phase 3 trials, receiving FDA approval, and launching Ohtuvayre® for chronic obstructive pulmonary disease. Under his leadership, Verona raised more than $1 billion to support development and commercialization and became one of the top-performing biotechnology companies on Nasdaq in 2024 based on its five-year increase in market value. Dr. Zaccardelli was recognized as Executive of the Year at the 2023 Scrip Awards. Currently, he serves as Chair of the Board of Directors for SAB BIO and Founder and Managing Member of Bull City Select Investments, LLC. Prior to Verona, Dr. Zaccardelli served as President and Chief Executive Officer of Dova Pharmaceuticals, a rare disease company acquired by Swedish Orphan Biovitrum in 2019 for up to $915 million. He previously served as Acting Chief Executive Officer of Cempra through its merger with Melinta Therapeutics and held several senior leadership roles at United Therapeutics Corporation, including Chief Operating Officer, Chief Manufacturing Officer and Executive Vice President, Pharmaceut...

View stock analysis, news, and events for Vor Biopharma Inc.